| FRA | fibrinogen-related antigen; fluorescent rabies antibody |
|---|---|
| HPA | Health Care Practice Act; Health Policy Agenda for the American People; health promotion advocates; ... |
| kf | flocculation rate in antigen-antibody reaction |
| PLA | peripheral laser angioplasty; phenyl lactate; phospholipase A; phospholipid antibody; placebo therap... |
| SA | salicylic acid; saline [solution]; salt added; sarcoidosis; sarcoma; scalenus anticus; secondary ame... |
| fluorescent treponemal antibody-absorption test | <investigation> A sensitive and specific serologic test for syphilis. It is more specific than the VDRL assay. The patient's serum is diluted to remove non-specific antibodies and then mixed on a glass slide with Nichol's strain of Treponema pallidum. If antibodies are present in the patient's serum they bind to the antigen and the bound antibodies are detected with fluoresceinated antihuman gamma-globulin antibody. Synonym: FTA-ABS test. (12 Sep2002) |
|---|---|
| Forssman antibody | A heterogenetic antibody specific for the Forssman group of heterogenetic antigens. Synonym: heterophil antibody, heterophile antibody. (05 Mar 2000) |
| lyme disease antibody | A blood test which measures for the presence of Lyme disease antibodies. A nonreactive or serum titre of less than 1:256 is normal. A rising titre over time is more diagnostic. False positives due occur in those with rheumatoid arthritis and lupus. (27 Sep 1997) |
| acetone-insoluble antigen | A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis. (18 Nov 1997) |
| allogeneic antigen | Genetic variations of the same antigens within a given species. (05 Mar 2000) |
| antigen | Virus coded cell surface antigens that appear soon after the infection of a cell by virus, but before virus replication has begun. See: early gene. (18 Nov 1997) |
| antigen-binding site | <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope). Also used of the site on a ligand molecule to which a cell surface receptor binds. (18 Nov 1997) |
| antigen-combining site | See: paratope. (05 Mar 2000) |
| antigen excess | In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases. (05 Mar 2000) |
| antigen interferon | <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation. This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity. Synonym: antigen interferon, immune interferon. Pharmacological action: antineoplastic agent, antiviral agents. (20 Sep 2002) |
| antigen p150,95 | A major adhesion-associated heterodimer molecule expressed by human monocytes, granulocytes, nk cells, and some lymphocytes. The alpha subunit is the CD11c antigen (also called leu-m5), a surface antigen expressed on some myeloid cells. The beta subunit is the CD18 antigen (antigens, CD18). The p150,95 antigen has been shown to play an important role in cell-cell and cell-substrate adhesive interactions. (12 Dec 1998) |
| antigen presentation | A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin. See: MHC restriction, histocompatibility antigens. (18 Nov 1997) |
| antigen presenting cell | A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin. See: MHC restriction, histocompatibility antigens. (18 Nov 1997) |
| antigen-presenting cells | Immunocompetent cells, usually ia positive, that mediate the cellular immune response by processing and presenting antigens or mitogens which stimulate T-cell activation. (12 Dec 1998) |
| antigen processing | Modification of an antigen by accessory cells. This usually involves endocytosis of the antigen and either minimal cleavage or unfolding. The processed antigen is then presented in modified form by the accessory cell. (18 Nov 1997) |